Pharmaceutical product permissions

A searchable record of what Walter is equipped to evaluate.

Explore compositions across oral solids, oral liquids, sterile injectables, topical formats and selected specialist presentations. Use the catalogue to begin a technical and commercial discussion—not as a substitute for written facility-specific confirmation.

5,500Distinct records
21Dosage forms
407Sterile injectable records
17Therapeutic indexes

Built for portfolio teams

Move from a molecule search to a focused feasibility conversation.

The catalogue brings together composition, strength, pharmacological class, dosage form, manufacturing stream, BCS class and documented regulatory references. It also incorporates products listed in Walter’s March 2025 Injectables Manufacturing Profile. Therapeutic and pharmacological classes are practical navigation labels; final indication, regulatory position and site suitability are confirmed product by product.

Search the catalogue

Selected catalogue briefs

Explore a composition for your manufacturing brief.

Browse selected compositions by dosage form, then share the required strength, pack, quantities and target market for a product-specific feasibility review.

Search the full catalogue
Browse 26 selected composition briefs

Therapeutic index

Begin with the treatment area.

Each composition is assigned to one practical primary area for navigation. Combination products may span more than one clinical use and remain subject to product-specific review.

Searchable permissions catalogue

Find a composition, dosage form or capability route.

5,500distinct permission records

Loading full catalogue search…
Therapeutic area
Dosage-form family
Specific dosage form
Pharmacological class
Manufacturing stream
BCS classification
Confirmed CDSCO category
Drugs Rules status

24 records shown

ImmunologyPRM 2897
Dosage formTablets
Oral

Azathioprine 100 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antimetabolite immunosuppressant
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 2898
Dosage formTablets
Oral

Azathioprine 25 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antimetabolite immunosuppressant
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 2899
Dosage formTablets
Oral

Azathioprine 75 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antimetabolite immunosuppressant
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 2930
Dosage formTablets
Oral

Baricitinib 1 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
JAK inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 2931
Dosage formTablets
Oral

Baricitinib 2 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
JAK inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 2932
Dosage formTablets
Oral

Baricitinib 4 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
JAK inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 3565
Dosage formTablets
Oral

Everolimus 0.25 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
mTOR inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 3566
Dosage formTablets
Oral

Everolimus 0.5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
mTOR inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 3567
Dosage formTablets
Oral

Everolimus 0.75 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
mTOR inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 3568
Dosage formTablets
Oral

Everolimus 1.0 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
mTOR inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 5532
Dosage formOral suspension
Oral

Mycophenolate Mofetil 200 mg / ml

Route
Oral
Formulation type
Oral liquid suspension
Pharmacological class
Antimetabolite immunosuppressant
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 5052
Dosage formHard-gelatin capsules
Oral

Mycophenolate Mofetil 250 mg

Same composition also available as

Tablets

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Antimetabolite immunosuppressant
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 4163
Dosage formTablets
Oral

Mycophenolate Mofetil 250 mg

Same composition also available as

Hard-gelatin capsules

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antimetabolite immunosuppressant
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 5053
Dosage formHard-gelatin capsules
Oral

Mycophenolate Mofetil 500 mg

Same composition also available as

Tablets

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Antimetabolite immunosuppressant
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 4164
Dosage formTablets
Oral

Mycophenolate Mofetil 500 mg

Same composition also available as

Hard-gelatin capsules

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antimetabolite immunosuppressant
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 4165
Dosage formTablets
Oral

Mycophenolate Mofetil 750 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antimetabolite immunosuppressant
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 4166
Dosage formTablets
Oral

Mycophenolate Sodium 540 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antimetabolite immunosuppressant
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 4167
Dosage formTablets
Oral

Mycophenolic Acid 180 mg (DR)

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antimetabolite immunosuppressant
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 4168
Dosage formTablets
Oral

Mycophenolic Acid 360 mg (DR)

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antimetabolite immunosuppressant
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 5131
Dosage formHard-gelatin capsules
Oral

Tacrolimus 0.25 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Calcineurin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 5132
Dosage formHard-gelatin capsules
Oral

Tacrolimus 0.5 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Calcineurin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 5133
Dosage formHard-gelatin capsules
Oral

Tacrolimus 0.75 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Calcineurin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 5134
Dosage formHard-gelatin capsules
Oral

Tacrolimus 3 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Calcineurin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

ImmunologyPRM 5135
Dosage formHard-gelatin capsules
Oral

Tacrolimus 5 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Calcineurin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Explore the product catalogue

Browse product pages by therapeutic area.

Browse compositions, strengths and dosage forms for third-party and contract manufacturing enquiries. Each product page includes its catalogue specification, manufacturing and packaging considerations, and a product-specific enquiry link. Confirm the applicable unit, documents and commercial terms with Walter.

How to read this catalogue

Permission is a starting point—not a supply commitment.

01

Therapeutic index

Primary areas provide buyer-friendly navigation. Combination products may reasonably sit across several clinical categories.

02

Facility confirmation

Current licence scope, site allocation, equipment fit and applicable segregation requirements are checked before commitment.

03

Product feasibility

Formula, strength, presentation, pack, target market, testing requirements and commercial scale are assessed together.

04

Responsible use

This B2B catalogue is not prescribing information, patient guidance or a representation that every composition is currently available for sale.

Start the conversation

Found a composition worth discussing?

Use the enquiry link on any record to carry its composition and dosage form into your manufacturing brief.

Request a quote
Quick chat on WhatsAppLet’s discuss your product